HK Stock Market Move | WUXI BIO (02269) up by over 3%. The company has reached a research service cooperation agreement with DuoXin Biotechnology and Aadi on three innovative ADCs.

WUXI BIO (02269) rose more than 3%, rallying 2.94% as of press time, to 17.52 Hong Kong dollars, with a turnover of 261 million Hong Kong dollars. On the news front, on December 20th, WUXI BIO announced a research service cooperation agreement with Hangzhou Dual-Dixy Biological Technology Co., Ltd. and Aadi Bioscience to support Aadi in the development of three next-generation antibody-drug conjugates (ADCs) in pre-clinical stage. Under the terms of the agreement, Aadi will pay WUXI BIO and Dual-Dixy Biological a first payment of 44 million US dollars, up to 265 million US dollars in development milestone payments, 540 million US dollars in commercial milestone payments, and a single-digit percentage of sales royalties.